ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 182 filers reported holding ARCUS BIOSCIENCES INC in Q1 2023. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,681,707 | +51.0% | 205,109 | +70.9% | 0.68% | +59.6% |
| Q2 2023 | $2,438,195 | +29.8% | 120,049 | +16.6% | 0.42% | +3.4% |
| Q1 2023 | $1,878,483 | +3.9% | 102,987 | +17.8% | 0.41% | -15.1% |
| Q4 2022 | $1,808,673 | -49.9% | 87,460 | -36.6% | 0.48% | -53.0% |
| Q3 2022 | $3,607,000 | -16.9% | 137,894 | -19.5% | 1.02% | -35.9% |
| Q2 2022 | $4,339,000 | -17.8% | 171,214 | +2.3% | 1.60% | +3.4% |
| Q1 2022 | $5,281,000 | +11.4% | 167,321 | +42.9% | 1.55% | +47.8% |
| Q4 2021 | $4,739,000 | -42.6% | 117,099 | -50.5% | 1.05% | -49.9% |
| Q3 2021 | $8,252,000 | +21.8% | 236,637 | -4.1% | 2.09% | +41.0% |
| Q2 2021 | $6,773,000 | -23.6% | 246,637 | -21.9% | 1.48% | -28.1% |
| Q1 2021 | $8,870,000 | +47.4% | 315,882 | +36.3% | 2.06% | +33.6% |
| Q4 2020 | $6,016,000 | +49.3% | 231,758 | -1.4% | 1.54% | +44.4% |
| Q3 2020 | $4,029,000 | +1.8% | 235,038 | +46.9% | 1.07% | -4.3% |
| Q2 2020 | $3,958,000 | – | 160,000 | – | 1.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $50,877,000 | 22.64% |
| Octagon Capital Advisors LP | 2,489,974 | $78,584,000 | 16.99% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $27,451,000 | 8.41% |
| BVF INC/IL | 3,960,948 | $125,008,000 | 5.00% |
| PFM Health Sciences, LP | 3,431,010 | $108,283,000 | 4.05% |
| EcoR1 Capital, LLC | 3,265,101 | $103,047,000 | 3.22% |
| Alphabet Inc. | 2,563,441 | $80,902,000 | 2.62% |
| Boxer Capital, LLC | 1,432,200 | $45,200,000 | 2.32% |
| SECTORAL ASSET MANAGEMENT INC | 338,480 | $10,682,000 | 1.90% |
| PARK CIRCLE Co | 64,000 | $2,020,000 | 1.68% |